Jun. 16 at 7:00 PM
All commercial-stage non-oncology focused bios off 7% or more from closing highs the last 5 trading days. We'll ignore Sarepta.
We're unaware of any adverse news around
$TGTX nor the bios noted below. Many believe TGTX is a compelling M&A candidate over the next 12 months.
$CPRX is one of the best performing bios in this peer group the last 5 years.
$AKBA is up 200%+ this year.
$BHVN had a PDUFA date that was extended. Troriluzole is expected to be a
$1B+/year therapy in spinocerebellar ataxia. Recall Reata was acquired by Biogen 5 months after their approval for Friedrich Ataxia.
$HRMY has a FY30 patent expiration on its lead therapy. A data read is nearing that would, in substance, protect its franchise.
This is for entertainment purposes only. This is not investment advice.
